FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial compares the effect of FDG-positron emission tomography (PET)-guided metastasis directed radiation therapy (MDRT) in combination with standard treatments to standard treatments alone in treating patients with prostate cancer that is sensitive to androgen-deprivation therapy (ADT) and has spread from where it first started (primary site) to other places in the body (metastatic). Prostate cancer is the second leading cause of cancer death among men in the United States, despite the approval of several life-prolonging treatments by the Food and Drug Administration. However, over the past 10 years, there have been significant improvements in prolonging the lives of those with metastatic hormone sensitive prostate cancer, specifically by adding treatments to standard therapy, such as ADT. More recently, trials have demonstrated a benefit of using radiotherapy (high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors) to delay the progression of cancer and prolong life for patients with metastatic disease. Imaging scans with FDG-PET may be able to identify cancer sites that remain active despite standard treatment. Giving MDRT plus standard treatment to patients with FDG-PET-identified cancer sites may work better than standard treatment alone in treating metastatic hormone sensitive prostate cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony zaawansowany rak prostaty widoczny w badaniach obrazowych (TK, MRI lub skaning kości)
- •Wiek co najmniej 18 lat
- •Ogólny stan zdrowia oceniony jako 0-3 w skali ECOG (pacjent jest w stanie samodzielnie się poruszać i pracować)
- •Cohort 1: Pacjent planuje chemioterapię, ewentualnie z dodatkowymi lekami hormonalnymi, lub jest w trakcie/ukończył taką terapię (w ciągu roku od początku)
- •Cohort 2: Pacjent planuje leczenie hormonalne bez chemioterapii, ewentualnie z dodatkowymi lekami
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 8, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (6)
Northwestern University
Chicago, United States
Northwestern Medicine: Kishwaukee
DeKalb, United States
Northwestern Medicine: Delnor
Geneva, United States
Northwestern University Oak Brook IL453
Oak Brook, United States
Northwestern Medicine Orland Park
Orland Park, United States
Northwestern Medicine: Warrenville
Warrenville, United States
Trial contact
Study Coordinator
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.